Tricare plans to expand its coverage of drugs used to treat premenopausal women with low sexual desire, a Tricare official said via email Feb. 12. Over the last five years, the Food and Drug Administration has approved two drugs to treat women with hypoactive sexual desire disorder (HSDD): the daily pill Addyi in 2015, and a self-administered injection, Vyleesi, in 2019. Read more on Military.com.